Talactoferrin in Severe Sepsis

Jean Louis Vincent; John C. Marshall; R. Phillip Dellinger; Steven G. Simonson; Kalpalatha K. Guntupalli; Mitchell M. Levy; Mervyn Singer; Rajesh Malik

doi:10.1097/ccm.0000000000001090

Article2007

Drotrecogin alfa (activated): the treatment for severe sepsis?

Jean Louis Vincent

Article2006

Drotrecogin alfa (activated) in the treatment of severe sepsis

Jean Louis Vincent

Article2000

A Double-Blind Placebo-Controlled Study of an Infusion of Lexipafant (Platelet-Activating Factor Receptor Antagonist) in Patients with Severe Sepsis

Yupin Suputtamongkol, Sunanta Intaranongpai, Michael D. Smith, Brian Angus, Wipada Chaowagul, Chairat Permpikul, J. A. Simpson, Amorn Leelarasamee, Lloyd Curtis, Sir Nicholas White

Antimicrobial Agents and Chemotherapy

Article2007

A Randomized Controlled Trial of Granulocyte Colony-Stimulating Factor for the Treatment of Severe Sepsis Due to Melioidosis in Thailand

Allen C. Cheng, Direk Limmathurotsakul, Wirongrong Chierakul, Nongluk Getchalarat, Vanaporn Wuthiekanun, Dianne Stephens, Nick Day, Sir Nicholas White, Wipada Chaowagul, Bart J. Currie, Sharon J. Peacock

Clinical Infectious Diseases

Letter2021

Circulating pentraxin 3 in severe COVID‐19 or other pulmonary sepsis

Alessandro Protti, Jennifer Meessen, Barbara Bottazzi, Cecília Garlanda, Angelo Milani, Monica Bacci, Alberto Mantovani, Maurizio Cecconi, Roberto Latini, Pietro Caironi

Talactoferrin in Severe Sepsis

Abstract

Discussion(0)

Related publications

Drotrecogin alfa (activated): the treatment for severe sepsis?

Drotrecogin alfa (activated) in the treatment of severe sepsis

A Double-Blind Placebo-Controlled Study of an Infusion of Lexipafant (Platelet-Activating Factor Receptor Antagonist) in Patients with Severe Sepsis

A Randomized Controlled Trial of Granulocyte Colony-Stimulating Factor for the Treatment of Severe Sepsis Due to Melioidosis in Thailand

Circulating pentraxin 3 in severe COVID‐19 or other pulmonary sepsis